Copyright
©The Author(s) 2021.
World J Gastroenterol. May 7, 2021; 27(17): 1847-1863
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.1847
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.1847
Figure 2 Main targeted drugs under study for patients with advanced pancreatic ductal adenocarcinoma.
EGFR: Epidermal growth factor receptor; TGFβ: Transforming growth factor β; APC: Antigen presenting cells; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death protein ligand 1; CAR-T: Chimeric antigen receptor T cells.
- Citation: Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863
- URL: https://www.wjgnet.com/1007-9327/full/v27/i17/1847.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i17.1847